Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome profiling by RNA-sequencing of the AML cell line MOLM-13.

ABSTRACT: Transcriptome profiling by RNA-sequencing of the AML cell line MOLM-13.

PROVIDER: PRJNA763889 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15914008_1.fastq.gz	Fastqsanger.gz
	SRR15914008_2.fastq.gz	Fastqsanger.gz
	SRR15914009_1.fastq.gz	Fastqsanger.gz
	SRR15914009_2.fastq.gz	Fastqsanger.gz
	SRR15914010_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Mitochondrial Fission 1 (FIS1) knockdown effect on the transcriptome of leukemia cell line MOLM-13 cells

Project description:To explore the function of Mitochondrial Fission 1 (FIS1) in acute myeloid leukemia (AML), we used shRNA to knock down the expression of FIS1 in leukemia cell line MOLM-13 cells and performed RNA-seq experiments to profile transcriptional changes upon FIS1 depletion.

2018-06-01 | GSE114111 | GEO

Transcriptional profiling of MOLM-13 AML cells following KAT6A CRISPR targeting

Project description:RNA-seq analysis of MOLM-13 human leukemia cells transduced with lentivirus containing CRISPR-Cas9 EV or sgKAT6A for 5 days

2021-10-20 | GSE156948 | GEO

RNA-seq of the human acute myeloid leukemia cell line MOLM-13 treated with the METTL3 inhibitor UZH2 for 16 h compared to untreated controls

Project description:The METTL3 methyltransferase is responsible for the deposition of N6-methyladenosine (m6A) modifications in RNA and has been identified as essential for survival and proliferation of acute myeloid leukemia (AML) cells in a genome-wide CRISPR screen. In our experiments involving a small-molecule METTL3 inhibitor (UZH2) in the AML cell line MOLM-13, we observed suppression of cell proliferation, induction of apoptosis and differentiation. The aim of RNA-seq experiment was to characterize the transcriptomic changes occurring in MOLM-13 cell line after treatment UZH2. Cell were treated with 10 µM of UZH2 for 16 h and compered to untreated controls (5 % DMSO).

2022-10-01 | E-MTAB-11952 | biostudies-arrayexpress

Transcriptional profiling of MOLM-13 AML cells following KAT6A CRISPR targeting

Project description:Transcriptional profiling of MOLM-13 AML cells following KAT6A CRISPR targeting

| PRJNA659646 | ENA

ChIP-seq analysis of HA-KAT6A in MOLM-13 AML cells

Project description:ChIP-seq analysis of MOLM-13 human leukemia cells with overexpression of WT KAT6A with HA tag.

2021-10-20 | GSE157039 | GEO

ChIP-seq analysis of HA-KAT6A in MOLM-13 AML cells

Project description:ChIP-seq analysis of HA-KAT6A in MOLM-13 AML cells

| PRJNA659932 | ENA

Transcriptome profiling by RNA-sequencing of the AML cell line MOLM-13.

Project description:All-trans retinoic acid (ATRA, RA) has powerful activity in APL; its efficacy in non-APL AML is still unclear, but may be boosted by epigenetic drugs such azanucleoside DNMT inhibitors (Blagitko-Dorfs et al. PLoS ONE 2013). In a randomized phase II study (DECIDER trial, NCT00867672) the addition of RA to decitabine (DAC) in newly diagnosed non-fit older AML patients resulted in a clinically meaningful extension of survival. We hypothesize that in vitro, the add-on of RA to DAC results in cooperative transcriptome changes (possibly associated with demethylation), which may explain at least in part this clinical result.

2022-08-31 | GSE184282 | GEO

Mitochondrial Fission 1 (FIS1) knockdown effect on the H3K27Ac status of leukemia cell line MOLM-13 cells

Project description:To examine if loss of FIS1 would alter the H3K27Ac status of leukemic cells, we used shRNA to knock down the expression of FIS1 in leukemic cell line MOLM-13 cells and performed H3K27Ac CHIP-seq to characterize any changes in the H3K27Ac marks upon loss of FIS1.

2018-06-01 | GSE114106 | GEO

MOLM-13 DDX6 KD proteomics to study RNA sequestration in Pbodies

Project description:Proteomics data associated with DDX6-depleted MOLM-13 cell line to study RNA sequestration mechanism in leukemogenesis.

2022-12-27 | MSV000090973 | MassIVE

RNA-seq of MOLM-13 acute myeloid leukemia cell line treated with FIDAS-5

Project description:MOLM-13 acute myeloid leukemia cells were treated with 3 µM FIDAS-5 methionine S-adenosyltransferase 2A (MAT2A) inhibitor or 0.1% DMSO as control for 48 hours

2023-04-22 | E-MTAB-12847 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data